Avacta Group has entered into a collaboration agreement with analytical instrumentation company Bruker to analyse the Affimer-based, bead-assisted mass spectrometry (BAMS) SARS-CoV-2 assay.

The assay has been developed by Avancta in partnership with Adeptrix.

Avacta and Adeptrix have developed a Covid-19 antigen test that merges the sample enrichment using Affimer reagents with the analytical power of mass-spectrometry.

Using a BAMS assay, a single technician can analyse up to 1,000 samples a day.

This is beyond the commonly used PCR machines’ capacity, thereby making BAMS a potentially high-throughput technique for Covid-19 screening to be used in the clinical setting.

On developing a prototype test with Adeptrix, Avacta has been working with its clinical partners in the UK to improve the assay to be incorporated into the typical workflows in a clinical microbiology lab.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through the latest partnership with Bruker, the company will analyse the suitability of the test as a professional-use in-vitro diagnostic (IVD) product for Covid-19 to run on Bruker’s MALDI-TOF instruments for sale in the UK and Europe.

Avacta Group CEO Dr Alastair Smith said: “I am delighted to have established this collaboration agreement with Bruker to further develop the potential for the BAMS Co vid-19 test as a clinical IVD.

“We will be working closely with Bruker on the clinical assessment of the BAMS assay on Bruker’s MALDI-TOF instruments.

“Our objective is to work with Bruker and our clinical partners to deliver an effective and high-throughput assay protocol, that can be applied in the clinical setting, with the required sensitivity and specificity and CE/FDA approvals to provide a useful additional diagnostic tool in the fight against the coronavirus.”

Last month, Bruker announced the launch of a CE-marked FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel which can detect SARS-CoV-2 virus of influenza A and B viruses and respiratory syncytial virus (RSV) with high sensitivity.